Systemic treatment for blepharokeratoconjunctivitis in children

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 5, 2016, Pages

  O'Gallagher, Michael ^a   Banteka, Marina ^a   Bunce, Catey ^a   Larkin, Frank ^a   Tuft, Stephen ^a   Dahlmann Noor, Annegret ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ARTIFICIAL TEAR; AZATHIOPRINE; BETA LACTAM ANTIBIOTIC; ESSENTIAL FATTY ACID; MACROLIDE; MYCOPHENOLATE MOFETIL; PLACEBO; PREDNISOLONE; TETRACYCLINE DERIVATIVE;

ABDOMINAL PAIN; ADOLESCENT; ADRENAL INSUFFICIENCY; ANTIBIOTIC THERAPY; ARTHRALGIA; BIBLIOGRAPHIC DATABASE; BLEPHAROCONJUNCTIVITIS; BLEPHAROKERATOCONJUNCTIVITIS; BONE MARROW SUPPRESSION; CATARACT; CENTRAL DATABASE; CHILD; CHILD NUTRITION; COMPRESSION THERAPY; CONJUNCTIVA; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CUSHING SYNDROME; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DIETARY SUPPLEMENT; DRUG EFFICACY; DRUG SAFETY; EMBASE; EOSINOPHILIA; ESOPHAGUS DISEASE; ESOPHAGUS IRRITATION; EYE CARE; FEVER; GASTROINTESTINAL SYMPTOM; HEAT TREATMENT; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INFECTION; KERATOCONJUNCTIVITIS; LOOSE FECES; LYMPHOMA; MEDLINE; MEIBOMIAN GLAND DYSFUNCTION; MENTAL DISEASE; MUCOSA INFLAMMATION; NAUSEA; NEWBORN; OBSTRUCTIVE JAUNDICE; OSTEOPOROSIS; PATIENT COMPLIANCE; PHOTOTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; STEROID THERAPY; STOMACH ULCER; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TOPICAL TREATMENT; TREATMENT OUTCOME; VOMITING; WARM LID COMPRESS; WORLD HEALTH ORGANIZATION; BLEPHARITIS; PRESCHOOL CHILD;

ADOLESCENT; BLEPHARITIS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; KERATOCONJUNCTIVITIS;

EID: 84970039370     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD011750.pub2     Document Type: Review

References (48)

1. Asbell PA, Stapleton FJ, Wickström K, Akpek EK, Aragona P, Dana R, et al. The international workshop on meibomian gland dysfunction: report of the clinical trials subcommittee. Investigative Ophthalmology and Visual Science 2011;52(4):2065-85.
2. Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 2003;22(7):640-50.
3. Cehajic-Kapetanovic J, Kwartz J. Augmentin duoTM in the treatment of childhood blepharokeratoconjunctivitis. Journal of Pediatric Ophthalmology and Strabismus 2010;47(6):356-60.
4. Choi DS, Djalilian A. Oral azithromycin combined with topical anti-inflammatory agents in the treatment of blepharokeratoconjunctivitis in children. Journal of AAPOS 2013;17(1):112-3.
5. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
6. Dougherty BE, Nichols JJ, Nichols KK. Rasch analysis of the Ocular Surface Disease Index (OSDI). Investigative Ophthalmology and Visual Science 2011;52(12):8630-5.
7. Elder MJ, Bernauer W. Monitoring of activity and progression in cicatrising conjunctivitis. Developments in Ophthalmology 1997;28:111-22.
8. Erdinest N, Shmueli O, Grossman Y, Ovadia H, Solomon A. Anti-inflammatory effects of alpha linolenic acid on human corneal epithelial cells. Investigative Ophthalmology and Visual Science 2012;53(8):4396-406.
9. Farpour B, McClellan KA. Diagnosis and management of chronic blepharokeratoconjunctivitis in children. Journal of Pediatric Ophthalmology and Strabismus 2001;38(4):207-12.
10. Fenton JI, Hord NG, Ghosh S, Gurzell EA. Immunomodulation by dietary long chain omega-3 fatty acids and the potential for adverse health outcomes. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2013;89(6):379-90.
11. Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocular Surface 2003;1(3):107-26.
12. Geerling G, Tauber J, Baudouin C, Goto E, Matsumoto Y, O'Brien T, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science 2011;52(4):2050-64.
13. GRADEpro GDT. GRADEpro Guideline Development Tool [Software]. McMaster University, 2015 (developed by Evidence Prime, Inc.). Available from www.gradepro.org.
14. Gupta N, Dhawan A, Beri S, D'souza P. Clinical spectrum of pediatric blepharokeratoconjunctivitis. Journal of AAPOS 2010;14(6):527-9.
15. Hamada S, Khan I, Denniston AK, Rauz S. Childhood blepharokeratoconjunctivitis: characterising a severe phenotype in white adolescents. British Journal of Ophthalmology 2012;96(7):949-55.
16. Hamada S, Nischal K, Evans J. The activity and damage of blepharokeratoconjunctivitis in children. Journal of AAPOS 2013;17(1):e16.
17. Hammersmith KM, Cohen EJ, Blake TD, Laibson PR, Rapuano CJ. Blepharokeratoconjunctivitis in children. Archives of Ophthalmology 2005;123(12):1667-70.
18. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
19. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
20. Jones SM, Weinstein JM, Cumberland P, Klein N, Nischal KK. Visual outcome and corneal changes in children with chronic blepharokeratoconjunctivitis. Ophthalmology 2007;114(12):2271-80.
21. Klein JO. History of macrolide use in pediatrics. Pediatric Infectious Disease Journal 1997;16(4):427-31.
22. Krakauer T, Buckley M. Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines. Antimicrobial Agents and Chemotherapy 2003;47(11):3630-3.
23. Li DQ, Luo L, Chen Z, Kim HS, Song XJ, Pflugfelder SC. JNK and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells. Experimental Eye Research 2006;82(4):588-96.
24. Li DQ, Zhou N, Zhang L, Ma P, Pflugfelder SC. Suppressive effects of azithromycin on zymosan-induced production of proinflammatory mediators by human corneal epithelial cells. Investigative Ophthalmology and Visual Science 2010;51(11):5623-9.
25. Luo L, Li DQ, Doshi A, Farley W, Corrales RM, Pflugfelder SC. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Investigative Ophthalmology and Visual Science 2004;45(12):4293-301.
26. Meisler DM, Raizman MB, Traboulsi EI. Oral erythromycin treatment for childhood blepharokeratitis. Journal of AAPOS 2000;4(6):379-80.
27. Miljanović B, Trivedi KA, Dana MR, Gilbard JP, Buring JE, Schaumberg DA. Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. American Journal of Clinical Nutrition 2005;82(4):887-93.
28. Murphy BS, Sundareshan V, Cory TJ, Hayes D Jr, Anstead MI, Feola DJ. Azithromycin alters macrophage phenotype. Journal of Antimicrobial Chemotherapy 2008;61(3):554-60.
29. Nelson JD, Shimazaki J, Benitez-del-Castillo JM, Craig JP, McCulley JP, Den S, et al. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Investigative Ophthalmology and Visual Science 2011;52(4):1930-7.
30. Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsuhota K, et al. The international workshop on meibomian gland dysfunction: executive summary. Investigative Ophthalmology and Visual Science 2011;52(4):1922-9.
31. Paediatric Formulary Committee. British National Formulary for Children. London: BMJ Group, Pharmaceutical Press, RCPCH Publications Ltd, 2013.
32. Pinazo-Durán MD, Galbis-Estrada C, Pons-Vázquez S, Cantú-Dibildox J, Marco-Ramírez C, Benítez-del-Castillo J. Effects of a nutraceutical formulation based on the combination of antioxidants and ω-3 essential fatty acids in the expression of inflammation and immune response mediators in tears from patients with dry eye disorders. Clinical Interventions in Aging 2013;8:139-48.
33. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
34. Ritter JM, Lewis LD, Mant TGK, Ferro A. A Textbook of Clinical Pharmacology and Therapeutics. 5th Edition. London: Hodder Arnold, 2008.
35. Royal Pharmaceutical Society. British National Formulary. 6th Edition. London: BMJ Group, Pharmaceutical Press, 2013.
36. Sacchetti M, Baiardini I, Lambiase A, Aronni S, Fassio O, Gramiccioni C, et al. Development and testing of the quality of life in children with vernal keratoconjunctivitis questionnaire. American Journal of Ophthalmology 2007;144(4):557-63.
37. Sadrai Z, Hajrasouliha AR, Chauhan S, Saban DR, Dastjerdi MH, Dana R. Effect of topical azithromycin on corneal innate immune responses. Investigative Ophthalmology and Visual Science 2011;52(5):2525-31.
38. Sheppard JD Jr, Singh R, McClellan AJ, Weikert MP, Scoper SV, Joly TJ, et al. Long-term supplementation with n-6 and n-3 PUFAs improves moderate-to-severe keratoconjunctivitis sicca: a randomized double-blind clinical trial. Cornea 2013;32(10):1297-304.
39. Singer TR, Isenberg SJ, Apt L. Conjunctival anaerobic and aerobic bacterial flora in paediatric versus adult subjects. British Journal of Ophthalmology 1988;72(6):448-51.
40. Solomon A, Rosenblatt M, Li DQ, Liu Z, Monroy D, Ji Z, et al. Doxycycline inhibition of interleukin-1 in the corneal epithelium. Investigative Ophthalmology and Visual Science 2000;41(9):2544-57.
41. Sotozono C, Ang LP, Koizumi N, Higashihara H, Ueta M, Inatomi T, et al. New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome. Ophthalmology 2007;114(7):1294-302.
42. Sullivan BD, Cermak JM, Sullivan RM, Papas AS, Evans JE, Dana MR, et al. Correlations between nutrient intake and the polar lipid profiles of meibomian gland secretions in women with Sjögren's syndrome. Advances in Experimental Medicine and Biology 2002;506(Pt A):441-7.
43. Suzuki M, Massingale ML, Ye F, Godbold J, Elfassy T, Vallabhajosyula M, et al. Tear osmolarity as a biomarker for dry eye disease severity. Investigative Ophthalmology and Visual Science 2011;51(9):4557-61.
44. Szymczak M, Murray M, Petrovic N. Modulation of angiogenesis by omega-3 polyunsaturated fatty acids is mediated by cyclooxygenases. Blood 2008;111(7):3514-21.
45. Tamargo RJ, Bok RA, Brem H. Angiogenesis inhibition by minocycline. Cancer Research 1991;51(2):672-5.
46. Tomlinson A, Bron AJ, Korb DR, Amano S, Paugh JR, Pearce EI, et al. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Investigative Ophthalmology and Visual Science 2011;52(4):2006-49.
47. Viswalingam M, Rauz S, Morlet N, Dart JK. Blepharokeratoconjunctivitis in children: diagnosis and treatment. British Journal of Ophthalmology 2005;89(4):400-3.
48. Banteka M, O'Gallagher M, Bunce C, Larkin F, Tuft S, Dahlmann-Noor A. Systemic treatment for blepharokeratoconjunctivitis in children. Cochrane Database of Systematic Reviews 2015, Issue 6. [DOI: 10.1002/14651858.CD011750]